Open Label Extension Study Evaluating the Safety and Biological Activity of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, Administered Intra Muscularly Every 6, 5 or 4 Weeks in Acromegalic Patients [EXTENSION OF 700244567]
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Octreotide (Primary)
- Indications Acromegaly
- Focus Adverse reactions
- Sponsors Ambrilia Biopharma
Most Recent Events
- 19 May 2014 New trial record